Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Engulfment and cell motility 1(ELMO1), is a very conserved protein that mediates phagocytosis, migration and morphological changes in cells. ELMO1 is important for maintaining the homeostasis of organisms, and its abnormal expression is closely related to the clinical stage and prognosis of diabetic nephropathy, microbial infection, and malignant tumor. ELMO1 has been confirmed to be one of the sensitive genes of diabetic nephropathy and is also involved in the invasion and metastasis of tumor cells.
The Biological Role of ELMO1
The role of ELMO1 can be mainly reflected in the following aspects: (1) acting as a downstream substance of phosphatidylserine receptor cerebrovascular angiogenesis inhibitor 1 (BAI1) and synergizes with DOCK1 to activate the Rac1 downstream signaling pathway via Rac-GEF pathway, triggering cytoskeletal rearrangement and promoting integrin-mediated phagocytosis.; (2) promoting internalization of dead cells; (3) promoting neuronal growth factor-induced neurite outgrowth and participating in the morphogenesis of neuronal cells; (4) recruiting microtubule microfilament cross-linking factors on the surface of cell membranes to promote tubulin capture and ubiquitin-mediated formation of cellular pseudopods; (5) acting as a target for distant-less homeobox 1, Dlx1, and is selectively expressed in Reelin-positive [Re(+)] and Calretinin-positive [Cr(+)] interneurons, which are indispensable for the migration of activity-dependent intermediate neurons; (6) acting as a unique regulator of the endogenous mediator complex 31 (Med31), which is mainly located in the nucleus, increasing the expression of Med31 in the cytoplasm, promoting its ubiquitination, and jointly affecting the expression of cytokines IL10 and IL33.

Figure 1. ELMO1 directly transduces GPCR signaling to Rac1 to regulate F-actin dynamics in chemotaxing cells. (Youhong, et al. 2016)
ELMO1 and Diabetic Nephropathy
ELMO1 plays an important role in the pathogenesis of diabetic nephropathy (DN). Genome-wide association analysis (GWAS) and GoKinD study of Japanese (yellow), African American (black) and Caucasians (white) showed that mutations at the ELMO1 gene locus were associated with diabetic nephropathy. Genetic mutations in ELMO1 will result in increased expression of ELMO1 in the glomeruli of diabetic patients. The polymorphism site associated with DN of ELMO1 is at its transcription start position. The genetic polymorphism of ELMO1 is closely related to the development of glomerulosclerosis and the fibrosis process of the kidney under high glucose conditions. In addition, ELMO1 not only predicts the onset of kidney damage in diabetic nephropathy, but may also lead to kidney failure.
ELMO1 and Tumor Invasive Growth
ELMO1 is abnormally expressed in various malignant tumors including lung cancer, breast cancer, esophageal adenocarcinoma, ovarian cancer, thyroid cancer, rhabdomyosarcoma and glioma, and is closely related to the clinical stage and prognosis of the tumor. It is one of the genes associated with tumor cell migration.
Overexpression of ELMO1 was significantly positively correlated with the invasiveness of rhabdomyosarcoma. In ovarian cancer cell line SKOV3, downregulation of ELMO1 interacting protein DOCK180 directly leads to down-regulation of ELMO1, and cell proliferation, migration ability, and invasiveness are significantly inhibited, accompanied by changes in cell morphology, such as flaky pseudopodia and decreased formation of filopodia, suggesting that ELMO1 and DOCK180 support each other and synergistically stimulate the downstream effector Rac1, which regulates the malignant behavior of cell motility and ovarian cancer cells. Breast cancer studies have shown that expression of ELMO1 is associated with lymph node and distant metastasis, and knockout of ELMO1 can lead to lung metastasis in breast cancer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.